{
    "clinical_study": {
        "@rank": "89069", 
        "arm_group": [
            {
                "arm_group_label": "ipratropium", 
                "arm_group_type": "Experimental", 
                "description": "500 mcg four times a day"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre\n      trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese\n      peri-operative patients with COPD under general anaesthesia."
        }, 
        "brief_title": "Ipratropium Bromide in Peri-Operative COPD", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  All patients must sign an informed consent.\n\n          -  Male or female patients aged >= 50 years and <= 75 years\n\n          -  Patients must be current or ex-smokers with a smoking history of >= 10 pack-years.\n\n          -  All patients must be diagnosed with COPD and must meet the following spirometric\n             criterion: post-bronchodilator forced expiratory volume in 1 second (FEV1) < 70% of\n             forced vital capacity (FVC) at Screening Visit (Visit 1).\n\n          -  All patients have relatively stable COPD (i.e. have no COPD exacerbation within 4\n             weeks prior to Screening Visit).\n\n          -  All patients are about to receive selective surgical procedures of lobectomy or right\n             bilobectomy under general anaesthesia, whilst the estimated time of surgical\n             procedures lasts for not less than 2 hours, and the estimated time of general\n             anaesthesia lasts for not less than 3 hours and not longer than 5 hours.\n\n          -  Patients must be able to perform all study related procedures including technically\n             acceptable pulmonary function tests (PFTs).\n\n        Exclusion criteria:\n\n          -  Patients who need maintenance treatment of bronchodilators (including\n             anticholinergics, \u00df-agonists, xanthines).\n\n          -  Patients with a recent history (i.e. six months or less) of myocardial infarction\n\n          -  Patients with any unstable or life-threatening cardiac arrhythmia requiring\n             intervention or change in drug therapy during the last year\n\n          -  Patients with symptomatic chronic heart failure (i.e. New York Heart Association\n             functional class III-IV)\n\n          -  Known narrow angle glaucoma\n\n          -  Patients with prostatic hyperplasia or bladder neck obstruction with significant\n             symptoms\n\n          -  Patients with a history of asthma, allergic rhinitis or who have a blood eosinophil\n             count >= 600 / mm3 (0.6\u00d710^9/L). A repeat eosinophil count will not be conducted in\n             these patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "192", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943552", 
            "org_study_id": "244.2514"
        }, 
        "intervention": [
            {
                "arm_group_label": "placebo", 
                "description": "normal saline", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ipratropium", 
                "description": "ipratropium bromide", 
                "intervention_name": "ipratropium bromide", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bromides", 
                "Ipratropium"
            ]
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }, 
                    "name": "244.2514.86002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Peri-operative Intervention With Nebulized Ipratropium Bromide in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial.", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: China Food and Drug Administration (CFDA)"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change of FEV1 from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3)", 
            "safety_issue": "No", 
            "time_frame": "treatment day 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of FVC from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3)", 
                "safety_issue": "No", 
                "time_frame": "treatment day 3"
            }, 
            {
                "measure": "Main post-operative pulmonary complications (including pneumonia, atelectasis and acute respiratory failure) within three weeks after the surgery", 
                "safety_issue": "No", 
                "time_frame": "25 days"
            }, 
            {
                "measure": "Change of blood gas analyses from pre-bronchodilator at baseline to post-nebulization one day before the surgery (Treatment Day 3): arterial oxygen tension (PaO2) value, arterial oxygen saturation and arterial carbon dioxide tension (paCO2) value", 
                "safety_issue": "No", 
                "time_frame": "treatment day 3"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}